| Bromotetrandrine (W198) is a Class I new drug for anti-tumor in china. To illustrate its mechanism, a shotgun quantitative proteomics strategy employing 2D LC/MS/MS and trypsin catalyzed 18O labeling quantification was carried out in this study. Compared to normal Chronic leukemia cell line K562 and K562 induced by Tet, the proteome changes of K562 induced by W198 was investigated.In order to validate the quantitation by the 18O labeling, the analysis was done on an equivalent sample composed of the same amount labeled and unlabeled proteins from normally cultured cells to act as a reference to the comparative sample. A threshold of±2-fold change for deciding whether a protein concentration is changed was settled for the following experiments.Comparing the 155 identified soluble proteins'expression levels of the apoptosis starting up K562 cells after W198 induction and the normally cultured cells, 16 proteins were found with significantly altered expression levels after W198 treatment. 8 proteins were up-expressed including HMGB2, Peroxiredoxin-2, eIF4A-I, etc. 8 proteins were down-expressed including TCP-1, GRP94, GST-π, SFGHs, etc. Compared to K562 induced by Tet, 8 proteins of K562 were found with significantly altered expression levels after W198 treatment. 5 proteins were up-expressed including HSP 90-beta, 40S ribosomal protein S15a, etc. 3 proteins were down-expressed including Phosphoglycerate kinase 1, Isoform 5 of Interleukin enhancer-binding factor 3, etc. These repressed or activated proteins were the potential drug targets of W198, which would offer the candidate proteins for tumor diagnosis and treatments.
|
PDF Full Text Request